Curious about today's AI digest?ai-tldr.dev

Daily Digest

Pomegra Startups

Isomorphic Labs raises $5B Series C in 2026

Isomorphic Labs, the AI drug-discovery company, raised a $5B Series C to push its drug candidates toward clinical trials.

FundingBiotechMAJOR4 min read
Isomorphic Labs raises $5B Series C in 2026

Isomorphic Labs closed a $5 billion Series C co-led by Greenoaks and Sequoia Capital to move its first AI-designed drugs toward clinical trials, six months after its $2.1 billion Series B.

Key Takeaways

  • Isomorphic Labs raised a $5B Series C on Nov. 17, 2026, co-led by Greenoaks and Sequoia Capital.
  • Bloomberg reported a roughly $50B valuation; the company has not confirmed a figure.
  • Total funding since March 2025 reaches about $7.7B, with no drug yet in human trials.

Lead

Isomorphic Labs, the London-based drug-discovery company spun out of Google DeepMind in 2021, announced a $5 billion Series C on Nov. 17, 2026. Greenoaks and Sequoia Capital co-led the oversubscribed round. The company will use the money to mature its drug design engine, build clinical development infrastructure, and bring its first candidates into trials.

The round arrives six months after a $2.1 billion Series B led by Thrive Capital in May 2026. It also follows a $600 million first outside round in March 2025. Together the three rounds total about $7.7 billion.

Who Invested in the Series C?

Andreessen Horowitz joined as a new investor alongside the two co-leads. Every existing backer returned: Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

Isomorphic did not disclose a valuation. Bloomberg reported earlier this month that the company was seeking funds at about $50 billion. If that figure holds, the company's worth would have grown several-fold in under two years, with no clinical data to support it.

What Does Isomorphic Labs Actually Do?

Isomorphic builds AI models to design small molecules and other drug types. It says its in-house Isomorphic Drug Design Engine, or IsoDDE, is a unified set of simulation models that search large areas of chemical space across several therapeutic areas and drug modalities. The work grew out of DeepMind's AlphaFold protein-structure research, which earned Demis Hassabis and John Jumper the 2024 Nobel Prize in Chemistry.

The company reports positive preclinical results in oncology and immunology. It also runs partnered programs with Eli Lilly, Novartis and Johnson & Johnson. Hassabis serves as founder and CEO, and Max Jaderberg is president. Headquarters are in London, with offices in Cambridge, Massachusetts, and Lausanne, Switzerland.

Why Is the Clinical Trial Step the Real Test?

Clinical entry is the first point at which investors get evidence that cannot be benchmarked in a lab. Computational design has shortened the path to promising molecules, but most drug candidates still fail in humans on safety or efficacy. No Isomorphic-designed compound has yet been disclosed as dosed in a patient, and the company has not given a trial start date.

That gap shapes how the round reads. The Series B, by the same logic, funded the engine; this round funds the infrastructure to test what the engine produces. Building translational and clinical development capacity is slower and more expensive than training models, and it is where earlier AI drug-discovery firms have run into trouble.

How Does the Round Compare With Rivals?

A $5 billion raise is among the largest venture rounds ever recorded in biotech. It dwarfs the funding of most AI-first drug developers, many of which have raised hundreds of millions of dollars and already have molecules in human studies. Those companies have mixed results, which is the main argument skeptics make against pricing Isomorphic on promise alone.

The counterargument is that Isomorphic's pharma partnerships supply external validation and milestone revenue, and that its Alphabet ties provide compute and talent few competitors can match. Investors are paying for that position, and for the possibility that a single platform produces many candidates rather than one.

What Comes Next?

The near-term milestones are measurable. Investors will watch for the first regulatory filing to begin human testing, the first dosing, and any data from the Lilly, Novartis or J&J programs. A delay beyond the 2027 horizon many in the sector expect would put pressure on a valuation set well ahead of the evidence.

Capital is not the constraint. Isomorphic now holds one of the largest cash positions of any private biotech, and the question is how quickly it can convert it into clinical results.

Outlook

Isomorphic Labs has raised roughly $7.7 billion in 20 months on the strength of its AlphaFold lineage, its pharma partnerships and early preclinical results. The Series C removes funding risk and puts the burden on execution. Entry into clinical trials, and the first human data that follow, will determine whether the reported $50 billion valuation is justified.

More Startup News